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ABSTRACT
Heat Shock Protein 27 Inhibition of the Caspase Cascade in Human Breast Cancer
Cells
by
L. Joe Stafford
Dr. Stephen W. Carper, Examining Committee Chair 
Associate Professor o f  Chemistry 
University o f Nevada, Las Vegas.
Cells may die via a programmed cell death called apoptosis. Apoptosis can be 
triggered by many death signals, some o f which cause cytochrome c to be released from 
the mitochondria initiating the caspase cascade. When there is an over-expression of 
Heat Shock Protein 27 (HSP27), the cell does not obey the death signals that it receives.
In this study, the molecular mechanism for the HSP 27 inhibition o f the caspase cascade 
is described in human breast cancer cells that were engineered to constitutively express 
HSP 27. HSP 27 directly bound to cytochrome c and inhibited the activation o f caspase 9 
and caspase 3. In the presence o f an excess amount o f cytochrome c, the caq>ase cascade 
was reactivated. Granzyme B activated caspase 3 even in the presence of HSP 27. This
lU
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suggests the conclusion that HSP 27 is a novel inhibitor o f  apoptosis by binding to
cvtochrome c.
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CHAPTER I
INTRODUCTION
Cancer
The growth o f normal cells is regulated to meet the needs o f the cell, whereas 
cancer cells continually replicate without any regulation. With more and more invading 
cancer cells, function of normal cellular activity and tissues is inhibited (1,2). The 
transformation of a normal cell into a cancer cell must involve changes in cellular 
processes that are central to normal cells. These changes in the cancer cells might be due 
to chromosomal structure and are completely inherited at the cellular level to the 
daughter cells ( 1 ). A cancer cell with these mutations will never give rise to another 
normal cell (2,3). Cancerous cells can also have a faulty mechanism that prevents them 
from undergoing programmed cell death (apoptosis). Without the mechanism for cell 
death, the cancer cell will keep dividing to form ttunors in the tissue. In some breast 
cancers there is an elevated level o f Heat Shock Protein 27 (HSP 27). Breast cancers that 
over-express HSP 27 show a much higher recurrence o f breast cancer (4-6). These 
elevated levels o f HSP 27 also lead to a poor prognosis for the patient (4,5).
Heat Shock Protein 27 
Heat Shock Protein 27 (HSP 27) is expressed when cells undergo stress. In 
normal cells, HSP 27 is expressed at very low (basal) levels. When the cell is exposed to
I
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a heat shock, or cytotoxic chemicals, HSP 27 levels are increased (7). HSP 27 can be 
used as a marker for more aggressive cancers because HSP 27 can provide resistance to 
chemotherapeutic drugs (4). One o f the functions o f HSP 27 is as a molecular chaperone 
preventing unfolding and degradation of proteins (8-11 ). HSP 27 has also been reported 
to protect cells from imdergoing apoptosis by inhibiting caspase activation (12).
HSP 27 is also an estrogen responsive protein. Estrogen responsive means that if  
estrogen is added, the levels o f HSP 27 will increase. Once estrogen is added to 
cancerous cells. HSP 27 will be produced allowing the cancer cell to survive when a 
chemotherapeutic drug is applied. An elevated level o f HSP 27 in tumor cells results in 
less cellular death compared to basal levels of HSP 27 when cells are stimulated to die 
(5). HSP 27 can also protect estrogen receptor negative cells from cytotoxic drugs and 
heat shock (5,7). Therefore, based on these data, HSP 27 inhibits apoptosis by an 
undefined mechanism.
Apoptosis
Cells live and divide for a certain niunber of times and then will die by 
programmed cell death (apoptosis). Apoptosis is an active form o f cell death The 
characteristics o f apoptosis include plasma membrane blebbing, nuclear condensation, 
loss o f cell volume and DNA fragmentation (13-15). Another feature o f apoptosis 
includes the absence o f tissue inflammation and swelling (15,16). Apoptosis is critical 
during development and homeostasis and any alteration to the apoptotic pathway leads to 
a number of diseases. Diseases associated with a fauhy apoptotic pathway include
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
cancer, autoimmune disorders such as Alzheimer's disease, Parkinson's disease and 
spinal muscular atrophy (15,16).
There are several pathways that lead to apoptosis in cells. The major receptor 
apoptotic pathways are the TNF a  and Fas L (Figure 1, page 7). The TNF a  pathway 
results when TNF a  binds to the TNF a  I receptor, leading to activate procaspase 8 into 
caspase 8. Once caspase 8 is activated it will cleave other procaspase 8 molecules as well 
as other procaspase enzymes. The Fas pathway also activates caspase 8 and activates 
apoptosis through the cleaving o f the other caspases. Another apoptotic activating 
enzyme is granzyme B. Granzyme B is a serine protease that is released from T cells 
with another protein called perforin. Perforin forms a pore for granzyme B that can be 
used to enter the cell (17,18). Once the pore is formed, granzyme B enters the cell and 
starts to cleave at specific aspartic acid residue target rites (18,19). Granzyme B will 
cleave interleukin-IB- converting enzyme (ICE) and other apoptotic cysteine proteases 
such as caspases 8, 3, 4, and 5 (18,20). Once these cabases are activated, the cell is 
committed to die via apoptosis. The final apoptotic pathway, and the most relevant one 
to this study, are the actions of cytotoxic drugs on the mitochondria. When a cytotoxic 
drug is applied to cells, it somehow signals the mitochondria to release cytochrome c.
The bcl-2 family o f proteins form pores for the release o f cytochrome c from the 
mitochondria (20, 21). Once cytochrome c is released, cytochrome c binds to apoptotic 
protease activating factor-1 (Apaf-1 ), proca^ase 9 and dATP to form the apoptosome 
(21). The formation of this apoptosome initiates the caspase cascade.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Caspases and the Caspase Cascade 
Caspases are enzymes that degrade other proteins. These cysteine proteases 
cleave at aspartic residues, and derive their name from their function and substrate 
specificity (15,22). To date there are identified 11 caspases which are subdivided into 3 
groups. The ICE subfamily includes caspases 1, 4. 5 and 11, the CPP32 subfamily 
consists of caspases 3, 6, 7, 8, 9 and 10, and caspase 2 stands alone (15). This 
classification can be broken down into initiator caspases which have long prodomains 
like caspases 8 and 9 or effector caspases with short prodomains like caspases 3, 6, and 7 
(23-26). The effector caspases are responsible for apoptosis. These enzymes cleave 
cellular substrates such as poly (ADP-ribose) polymerase, and structural proteins like 
lamina and actin. They also degrade protein kinase C 6 that is involved in the cell cycle 
( 15,23,24,27). Caspase 3 is also responsible for cleaving the inhibitor protein for the 
caspase-activated endonuclease (1CAD). Without the inhibitor protein CAD (caspase 
activated DNase) cleaves DNA at the linker regions between nucleosomes which results 
in DNA fragmentation o f approximately 200 bas pairs (28).
Caspases are synthesized as zymogens, and thus are in an inactive form in the 
cell. Once the cell receives an apoptotic signal, a procaspase will be cleaved to a 
functional caspase. A fimctional ca^ase  can activate other cabases or cleave specific 
target proteins. There is a specific pathway that the caspases follow when a cell is treated 
with a cytotoxic drug; the so-called ca^ase cascade.
The caspase cascade is induced through the mitochondria (Figure 2, page 8). An 
apoptotic-inducing drug, such as sodium butyrate, releases cytochrome c from the 
mitochondria. Cytochrome c forms the apoptosome with procaspase9, dATP and Apaf-1
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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(21). The apoptosome then cleaves procaspase 9 activating it to caspase 9. Caspase 9 
then cleaves other procaspase 9 molecules or it can activate procaspase 3 to caspase 3, 
procaspase 6 to caspase 6. or procaspase 7 to caspase 7 (23,29,30). Once caspase 6 and 7 
are activated they will cleave their substrates. When caspase 3 is activated, it will cleave 
all the other caspases including caspases 1 and 8. Once caspase 3 is activated, cell death 
is inevitable. Caspase 3 is known as the '‘executioner" o f the cell. Another caspase 
cascade occurs when activated caspase 8 activates caspase 3 and all the other caspases 
(23.26). The caspase cascade of interest to this study is through the mitochondria. This 
is because sodium butyrate and other apoptotic drugs cause a release o f cytochrome c but 
do not interact with any other apoptotic pathways and do not activate caspase 8.
Sodium butyrate will release cytochrome c from the mitochondria but will not 
activate any other form of apoptosis or necrosis (20). Using a specific assay that 
measured DNA degradation between the nucleosomes, Sindhu Padmanabhan showed in 
her thesis that human breast cancer cells used in this thesis undergo apoptosis (31).
Using this result, it was determined to investigate the role of the caspase cascade in the 
HSP 27 mediated inhibition o f apoptosis.
Inhibitors o f Apoptosis 
Inhibitors o f apoptosis can hah caspase activation. The baculovirus protein p35 is 
an inhibitor o f all activated caspases (32). Crm A protein from the cowpox virus inhibits 
caspase 8 activation (32). The protein FLIP inhibits the Fas death inducing signal 
complex (DISC). Mammalian inhibitors o f apoptosis homologs B & C (MIHB and 
MEHC) inhibit the TNF DISC (33). These DISC inhibitors prevent the activation o f
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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caspase 8. The X- linked inhibitor o f apoptosis (XIAP) inhibits activated caspase 3, 7 
and 9 (34). HSP 27 has no sequence homology with any o f  these known inhibitors but 
still prevents the cell from undergoing apoptosis. HSP 27 might be inhibiting one o f  the 
caspases or it might be working up stream o f the caspases.
Significance o f the Study 
The main goal o f this study is to understand where HSP 27 is inhibiting the 
caspase cascade in breast cancer cells. From previous work it was shown that sodium 
butyrate will induce apoptosis in these cells and an over-expression o f HSP 27 will 
inhibit apoptosis. This project will determine if HSP 27 inhibits either caspase 3, 8, or 9 
or if it is acting prior to the activation of these caspases. The hypothesis for this study is 
that HSP 27 is inhibiting the caspase cascade by the inactivation o f caspase 3. The 
techniques that will be used to determine if  the hypothesis is correct, are colormetric 
assays, kinetic assays and western blot analysis.
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Active caspase 8
Figure 1 Receptor Mediated Apoptosis. The PAS ligand will bind to the FAS receptor 
This will activate FAS associated death domain (FADD) which will activate 
procaspase 8 to caspase 8. Caspase 8 will then activate procaspase 3 to active 
caspase 3. The protein FLIP will inhibit FADD from becoming active which 
will inhibit the formation o f active caspase 8. The other pathway is the Tumor 
Necrosis Factor alpha (TNF-a) I pathway. TNF-a will bind to its receptor 
and activate TNF-a receptor associated death domain (FADD). FADD will 
then activate procaspase 8 to active caspase 8 and the caspase 3 will become 
active once again. Mammalian inhibitors o f apoptosis homologs B & C 
(MIHB and MIHC) will inhibit TRADD so caspase 8 will not become active.
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Apoptotic drug.
Mitochondria
cytochrome c 
procaspase 9, dATP and Apaf-1
apoptosome
caqiase 9
procaspase 3
caspase 3
Other caspases Structural proteins Kinases CeU cycle[CAD
Figure 2 C a^ase Cascade Pathway. When a cytotoxic drug releases cytochrome c, h 
will bind to procaqiase 9, dATP, and Apaf-1 to form the apoptosome.
The apoptosome wiU then cleave procaq*ase 9 to form active ca^ase 9. 
Caspase 9 wiU then cleave procaspase 3 to active ca^ase  3. Once caspase 3 
is active it wUl cleave other caspases, structural proteins, kinases, ICAD 
(which results in DNA degradation), and cell cycle enzymes.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 2
MATERIALS AND METHODS 
Cell Lines
The cell lines that were used included DC 4, and DB 46. These cell lines were 
derived from an estrogen receptor-negative human breast cancer cell line MBA-MD-231 
The constitutive expression vector pB27 was used in constructing DB 46 cells whereas 
the control vector pHB-Apr-l-neo was used in constructing DC 4 cells (35). All cell 
lines were grown in Minimal Essential Media (MEM). MEM was supplemented with 
10% fetal bovine serum, 25mM HEPES buffer, lOOIU penicillin/ml, 100p.g/ml 
streptomycin, 2mM L-glutamine (Biowhhtaker Inc.), and 600)xg/ml G418 sulfate (Gibco 
BRL). Cells were kept at 37°C and in a 5% CO%: 95% air environment. Twenty-four 
hours before an experiment, the cells were placed in MEM lacking G418 (35).
Drugs and Proteins
Vitamin E Succinate (YES), cyclohexamide (CHX) and sodium butyrate (NaB) 
(all from Sigma Chemical Co.) were prepared at lOmg/ml, 100p.M and lOOmM, 
respectively, in deionized water and fiher sterilized (0.2p filter). HSP 27 was purchased 
from StressGen (Vancouver, BC) and resu^ended in a buffer containing 20mM Tris- 
HCL pH 7.5, 1 OOmM NaCl, 0.1 mM EDTA, and ImM DTT. Granzyme B ((MES pH 6.0 
with 400mM NaCl) (32,000 mOD min'Vml, Assayed with EUman’s to detect the HSBL
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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with 400mM NaCl) (32,000 mOD min'Vml, Assayed with Ellman's to detect the HSBL 
leaving group from 90pM Boc-Ala-Ala-Asp-Sbzl in 0.1 M HEPES pH 7.5 with 0.5M 
NaCl at 410nm) was a kind gift from Dr. Dorothy Hudry, University o f Nevada, Reno.
Cell Survival
DC 4 (-HSP 27) and DB 46 (+HSP 27) cells were exposed to either lOmM NaB, 
lOOmM CHX or lOmg/ml VES for one hour. The cells were then washed in PBS, 
resuspended in supplemented MEM, and 2000 cells were plated in 5ml of supplemented 
MEM in 60mm tissue cultme dishes. Cells were incubated at 37°C in a 5% CO;: 95% air 
incubator for fourteen days. After the incubation period, the media was removed and the 
cells were stained with crystal violet (5% Crystal violet: 95% ethanol), dried, and counted 
for colonies containing more that 50 cells (cell survived). Results are presented as a 
percent survivaL
Caspase 3 Time Course 
DC 4 (-HSP 27) and DB 46 (+HSP 27) cells were induced to undergo apoptosis 
with continuous exposure to lOmM NaB and assayed at the indicated times. After 0, 2, 4, 
and 6 hours, 5x10^  cells were washed with phosphate buffer saline (PBS) and 
centrifuged. Lysis buffer was added at IxIO^cells/ 25pi cells and the cells were 
incubated on ice for ten minutes. The cell suqiensions were then centrifuged at 14,000 x 
g for fifteen minutes at 4°C. Fifty microliters o f  lysate was added to 50pl o f assay buffer 
in a 96-well plate. Five microliters o f the substrate (Asp-Glu-Val-Asp-pNA) were added 
to each well. Following incubation at 37°C for one hour, the absorbance at 510 nm was
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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measured using a microplate reader (Dynatech MR5000). Results are presented as 
relative caspase 3 activity. Lysis buffer, assay buffer and substrate were used from a
caspase 3 assay kit (Clone Tech.).
Caspase 9 Time Course 
DC 4 (-HSP 27) and DB 46 (+HSP 27) cells were induced to undergo apoptosis 
at the indicated times with lOtnM NaB. Five million cells were washed with phosphate 
buffer saline and then resuspended in l.xloV 25 pi cells o f lysis buffer. Cells were 
incubated on ice for ten minutes and then centrifuged at 14,000 x g for fifteen minutes at 
4°C. Fifty microliters o f lysate were added to 50pl o f  assay buffer and then 5 pi of 
caspase 9 substrate were added (Leu-Ghi-His-A^-pNA). Following an incubation at 
37^C for one hour, the absorbance was read at 510nm on a microplate reader (Dynatech 
MR 5000). Results are presented as relative caspase 9 activity. The lysis buffer, assay 
buffer and substrate were obtained from Medical and. Biological Laboratories Co. LTD.
Ca^ase 3, 8 and 9 Kinetics 
Caspase 3 (Calbiochem) instructions were followed. Briefly, equimolar 
concentrations o f caqiase 3 and HSP 27 were added to wells in a 96 well plate, diluted to 
a volume of 90pL and incubated at room temperature for ten minutes. Ten microliters o f 
the substrate (DEVD-pNA) was added to wells and the plate was read every minute for 
45 minutes at 5 lOnm on a microplate reader (Dynatech MR 5000). Slopes of each line 
were compared and data reported as relative percent caspase activity.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Caspase 8 assay instructions were followed (Calbiochem). Briefly, equal molar 
concentrations of caspase 8 and HSP 27 were added to wells in a 96 well plate and 
diluted to a volume o f 90pL and incubated at room temperature for ten minutes. Ten 
microliters of the substrate (lETD-pNA) was added to the wells and the plate was read 
for every minute for 45 minutes at 5 lOnm on a microplate reader (Dynatech MR 5000). 
Slopes of each line were compared and data is presented as relative percent caspase 
activity.
Caspase 9 assay instructions were followed (Alexis). Equal molar concentrations 
of caspase 9 and HSP 27 or caspase 9 inhibitor were added to wells in a 96 well plate and 
brought up to a volume o f 90pL and incubated at room temperature for ten minutes. Ten 
micro liters of the substrate (LEHD-pNA) was added to the wells and the plate was 
analyzed for optical density every minute for 45 minutes at 5 lOnm Slopes of each line 
were compared and data is relative percent caspase activity
Immimoprecip nations
DC 4 cell (-HSP 27) extracts were prepared as follows: 5x10^ cells were washed 
in PBS and incubated in 600pl cytochrome c buffer (220mM mannhoL, 68mM sucrose, 
50mM PIPES-KOH, pH 7.4, 50mM KCl, 5mM EGTA, 2mM MgClj, ImM dithiothrehol 
(DTT) and I pill o f protease inhibitors (Complete Cocktail, Boehringer Maimheim)X36) 
for thirty minutes at room tenqierature. Cells were then homogenized for 40 strokes 
using a dounce homogenizer and a B pestle. Cells were then centrifuged for fifteen 
minutes at 14,000 x g. To the supernatant extract, 5 pi o f HSP 27 (Ipg/pl) and 5 pi 
cytochrome c ( ipg/pl) was added. The lysate was allowed to incubate for ten minutes at
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room temperature. The lysate was then divided into two samples. To one sample HSP 
27 antibody (StressGen) ( 1:200) was added and cytochrome c antibody (Pharmingen)
( 1 ;200) was added to the other sample. Samples were incubated on a lab quake for sixty 
minutes at 4°C To all samples 20pl o f A/G protein and agrose was added and samples 
were incubated for forty-five minutes on a lab quake at 4°C. Samples were centrifuged at
14.000 X g for 15 minutes, the supernatant discarded, and the pellet resu^ended in 
denaturing/reducing sample buffer ( 125mM Tris pH 7.4, 4% SDS, 10% glycerol, .005% 
Bromophenol Blue, 2% B-mercaptoethanol). Samples were electrophoresed on a 10.0% 
separating gel at lOOV for 45 minutes. The samples were then blotted (Bio Rad) for 
eighty minutes at I OOmV onto nitrocellulose paper. The nitrocellulose paper was 
transferred into blocking solution (0.5% Blotto, 0.05% BSA in IX TrisBorateSaline- 
Tween20 (TBST)) for 24 hours at 4°C. The primary antibodies ( 1:1000) were dissolved 
in 1X TBST, added to each paper, and allowed to shake for sixty minutes. The blots 
were then washed three times in IX TBST for ten minutes. The secondary goat anti 
mouse antibody (Pharmingen) was dissolved in IX  TBST ( 1:2500) and added to the 
membranes. This was then shaken for one hour at room temperature, and three more 
washes with IX TBST were performed. Finally, 1ml o f the chemilumensence substrate 
was added to each membrane and exposed to x ray film for thirty seconds. The results 
are shown on the western blots.
Cytochrome c Assays 
Five million DC 4 cells (-HSP 27) were harvested and washed in PBS Six 
hundred microliters o f  cytochrome c buffer were added to 2.5 x 10  ̂cells (220mM
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mannitol, 68mM sucrose, 50mM PIPES-KOH, pH 7.4, 50mM KCl, 5inM EGTA, 2mM 
MgC12. ImM dithiothrehol (DTT) with I o f  the pill protease inhibhors (Complete 
Cocktail, Boehringer Mannheim)X36). Following incubation for ten minutes on ice the 
cells were homogenized whh a dounce homogenizer with a B pestle for forty strokes.
Tlie cell lysate was then aliquoted into two 1.5ml microfuge tubes and centrifuged at
14.000 X g for fifteen minutes at 4°C (36). Cell lysate was used with the caspase 3 assay 
kit (Calbiochem). The volume of cell lysate (75pl) and substrate ( lOpl) remained 
constant and the amounts of 1 mg/ml cvtochrome c (Sigma) and assay buffer was varied 
for a final volume o f lOOp.1. Various concentrations o f HSP 27 (StressGen) and 
cvtochrome c (Sigma) were used in the experiments. Slopes of the line for thirty minutes 
were compared to the control and data is expressed as relative caqiase 3 activity.
A ca^ase  9 inhibhor (Leu-Glu-His-A^CHO) (Alexis) was used in two 
concentrations (5pl and lOpl) to determine if  caspase 9 was being activated in the 
caspase cascade. The above procedure was used and caspase 9 inhibhor was added prior 
to the start o f  the assay. The assay was conducted for thirty minutes and slopes o f the 
lines were compared to the control.
Granzyme B
Five million DC 4 cells ( HSP 27) were washed in PBS, and 600pl o f  cytochrome 
c buffer/2.5 x 10  ̂cells was added. Following an incubation on ice for ten minutes, the 
cells were homogenized whh a dounce homogenizer for forty strokes whh a B pestaL 
The cell lysate was then put into two 1.5ml microfuge tubes and centrifuged at 14,000 x g 
for fifteen minutes at 4°C. Cell lysate was used whh the caspase 3 assay kh as previously
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described (Calbiochera). The amount of lysate and substrate remained the same with 
additions of cytochrome c or granzyme B (either alone or in combination with equal 
molar amounts of HSP 27) being made 10 minutes prior to the assay. Assay buffer was 
used to bring the total volume up to 100^1. The kinetic assay was run for thirty minutes 
The slopes of the lines were compared to the control and data is reported as relative 
caspase activity.
Statistical Analysis
Results are reported as standard error o f  the means ± S.E.M. Statistical analysis 
was performed with a statistical software package (Student version of Ntinhab).
Statistical significance was determined by one-way ANOVA for repeated measurements 
followed bv a student t-test.
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CHAPTERS
RESULTS
HSP 27 Can Provide Long Term Protection from Différent Cytotoxic Drugs 
To determine if HSP 27 could prevent cell death (apoptosis) over long periods, a 
clonogenic cell survival assay was conducted, which measures viable cells fourteen days 
after exposure to cytotoxic drugs as described in chapter 2 (Materials and Methods). DC 
4 (-HSP 27) and DB 46 (+HSP 27) cells were each treated with lOmM sodium butyrate 
(NaB), or lOO^M cyclohexamide (CHX) or lOmg/ml vitamin E succinate (figure 3, page 
22). DC 4 cells (-HSP 27) cell survival was about 66.9% with lOOpM cyclohexamide 
compared to an 89.7% survival in the DB 46 cells (+HSP 27). With lOmM sodium 
butyrate DC 4 cells only had a 67.1% survival compared to 96.3% survival in the DB 46 
cells. With lOmg/ml vitamin E succinate DC 4 survival was 73.6% compared to 98.9% 
in the DB 46 cells. Over-expression o f HSP 27 protected cells from three different 
inducers o f  apoptosis during a two-week interval
HSP 27 Inhibits Caspase 3 Activity 
To determine if HSP 27 inhibits caspase 3 activation, a time course study was 
conducted as described in Material and Methods. Both DC 4 (-HSP 27) and DB 46 (+ 
HSP 27) cells were induced to undergo apoptosis with lOmM sodium butyrate (NaB) and 
assayed every two hours to determine if caspase 3 activation increases in one or both cell
16
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lines (figure 4,page 23). There was no increase in caspase 3 activation for the first four 
hours in either cell line. In the sixth hour the DC 4 (-HSP 27) cells showed a 2.5 fold 
increase in caspase 3 activation whereas DB 46 (+HSP 27) cells showed no increase in 
caspase 3 activation. Longer time courses were conducted for up to forty- eight hours in 
continuos exposure to NaB but there was no increase in caspase 3 activity in the HSP 27 
transfected cell line (data not shown). Therefore, HSP 27 appeared to inhibit caspase 3 
activation.
HSP 27 does not Directly Inhibit Caspase 3, Caspase 8, and Caspase 9 
To determine if HSP 27 can directly inhibit caspase 3 or caspase 8, kinetic assays 
were conducted as described in chapter 2. There was no difference between the control 
and HSP 27 values. The effects o f  equimolar amounts HSP27 showed no inhibitory 
function on the activity o f either caqrases 3 or 8 compared to the control (figure 5, page 
24). In addition, HSP 27 did not inhibit caspase 9 (figure 6, page 25). The control value 
was 100% and the HSP 27 plus caspase 9 value was 127% with standard deviations of 
20%. therefore there was no statistical difference between the two. When a caspase 9 
competitive inhibitor is present, activity dropped to about 36%. The competitive 
inhibitor will not totally inhibit caspase 9 activity. These results lead to the assumption 
that HSP 27 does not directly inhibit caq>ase activity.
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HSP 27 Inhibits Caspase 9 Activation 
To determine if HSP 27 inhibits caspase 9 activation a time course was conducted 
as described in the chapter 2. DC 4 (-HSP 27) and DB 46 (+HSP 27) cells were induced 
to undergo apoptosis with lOmM sodium butyrate (NaB) and assayed at 0, 15, 30 and 45 
minutes following sodium butyrate exposure. Within fifteen minutes caspase 9 was 
active with a 50% increase in the DC 4 (-HSP 27) cells while the DB 46 (+HSP 27) cells 
did not increase with any significance (figure 7, page 26). Longer caspase 9 time courses 
up to six hours were also performed but there was no increase in caspase 9 activation in 
the DB 46 (+HSP27) cells (data not shown). This leads to the conclusion that HSP 27 is 
inhibiting caspase 9 activation.
HSP 27 Binds Directly to Cytochrome c 
To determine if a direct interaction between HSP 27 and cytochrome c was 
occurring, HSP 27 and cytochrome c immunoprécipitations (IP) were conducted as 
outlined in chapter 2. Lane one o f the IP is the standard marker for cytochrome c (figure 
8, page 27). Lane two shows that the antibody for cytochrome c will bind to the 
cytochrome c. Lane three shows that there is a little cross reactivity between cytochrome 
c and the HSP 27 antibody. This might be due to the 6 c t that the HSP 27 antibody can 
recognize a denatured protein and bind to it. Lane four shows that when a cell fi'ee lysate 
is used, there is a small amount o f free cytochrome c in the lysate and not all in the 
mitochondria. This could be due to rupturing the mitochondria membranes during the 
preparation o f the cell lysate. This will cause a little cytochrome c to be in the cell lysate 
and not all in the mitochondria. In lane five once again there is a slight cross reactivity
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between the HSP 27 antibody and the free cytochrome c in the cell lysate. With the 
addition of cytochrome c in the cell lysate and probed with the HSP 27 antibody, there is 
a greater amount o f cross reactivity. This once again can be due to the fact that the HSP 
27 antibody may bind to denatured proteins. Lane 7 shows that when HSP 27, 
cytochrome c and the cytochrome c antibody is used there is a strong signal indicating 
that HSP 27 and cytochrome c form a complex. In lane 8, cytochrome c and HSP 27 are 
added together and precipitated with the HSP 27 antibody. Once again there was still a 
strong signal that indicates HSP 27 and cytochrome c form a complex. Therefore h was 
concluded that HSP 27 and cytochrome c form a complex in vitro.
Additions o f Cytochrome c Causes an Increase in Caspase 3 Activity in Cell Free
Extracts
A cell free extract system was utilized to determine the ability o f HSP 27 to 
inhibit the caspase cascade. A dose response to cytochrome c was performed in a cell 
free extract as described in chapter 2. With increasing amounts o f cytochrome c there is 
also an increase in caspase 3 activity (figure 9, page 28). With the addition o f O.Spg of 
cytochrome c there is about a 1-fold increase in caspase 3 activity. With Ipg o f 
cytochrome c there is about a 4.5 fold increase, with 2.5pg o f  cytochrome c it is about an 
11 fold increase and at 5pg there is about a 19 fold increase in ca^ase  3 activity. 
However, with lOpg of cytochrome c the dose response was only about 12 fold. At this 
highest dose o f cytochrome c tested, there was reduction o f caspase 3 activity. This 
reduction could be due to the changing o f  the ionic strength or it could be because too 
much cytochrome c would form aggregates and not be available in the formation o f the
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apoptosome. The dose response seen here has also been seen in other experiments (data 
not shown). It is concluded that cytochrome c can activate the caspase cascade in this 
cell- free extract.
Caspase 9 is in the Caspase Cascade 
Caspase 9 is activated during the addition of cytochrome c. This was 
demonstrated by adding a caspase 9 inhibitor and measuring caspase 3 activity (figure 10, 
page 29). This demonstrated that if caspase 9 is inhibited, then ca^ase  3 activity will be 
reduced. With the presence of cytochrome c there is an increase in caspase 3 activity 
which was reduced by the ca^ase 9 inhibitor. When the inhibitor is added it lowers the 
caspase 3 activation by about 65%. Since the caspase 9 inhibitor did not completely 
inhibit the caspase 9 activation other cabases might also be activating caspase 3. 
However, it should be noted that the caspase 9 inhibitor was not 100% effective against 
activated caspase 9 (Fig 6, page 25). This is due to the fact that the inhibitor is a 
competitive inhibitor and is concentration dependent. A conclusion can be made that a 
majority o f  the caspase 3 activation results from active caspase 9.
HSP 27 Inhibits Cytochrome c Activation of Caspase 3 in a Cell Free Lysate 
To confirm that HSP 27 binds to cytochrome c, a dose response to cytochrome c 
was conducted with or without the addition o f  5pg of HSP 27 to the cell free extract. The 
addition o f 2.5pg of cytochrome c resulted in a 2-fold increase in caspase 3 activity. 
However, in the presence of HSP 27, 2.5pg o f cytochrome c friled to increase the 
ca^ase  3 activity. With 5pg o f cytochrome c, there was about a 12 fold increase in 
caspase 3 activity. Again, in the presence o f  5pg of HSP 27, there was an inhibition o f
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
21
caspase 3 activity. With the addition o f I Opg of cytochrome c. there was an 11 fold 
increase in caspase 3 activity. In the presence of HSP 27, lOpg o f cytochrome c resulted 
in only a 3-fold increase in caspase 3 activity over the control (figure 11, page 30). This 
suggests, that with an excess o f  cytochrome c it may be possible to over-come the 
inhibitory effects o f HSP 27 and restart the apoptotic cascade. This trend has been seen 
in other experiments (data not shown).
Granzyme B can Overcome HSP 27 Inhibition o f Caspase 3 Activation in Cell Free
Extracts
To help confirm that HSP 27 acts at the level o f cytochrome c, cell fi’ee extracts 
were prepared as described in Chapter 2. To the extracts were added either 2pg of 
cytochrome c o r l p g  granzyme B. To other extracts were added 2pg cytochrome c with 
2pg HSP 27 or Ipg granzyme B and l^ g  HSP 27. In the presence o f 2pg o f cytochrome 
c there was about a 21-fold increase in ca^ase  3 activation (figure 12, page 31). With 
the addition of HSP 27 and cytochrome c there was about a 2-fold increase in caspase 3 
activation compared to the control (figure 12, page 31). The ability o f HSP 27 to inhibit 
cytochrome c activation of caspase 3 is also shown in figure 9 (page 28). In the presence 
of 1 )ig o f granzyme B there was about a 6 fold increase in caspase 3 activation. With the 
addition of granzyme B and HSP 27 there was about a 7 fold increase in caspase 3 
activity. Since HSP 27 did not decrease the caspase 3 activity with granzyme B, 
granzyme B may be activating caqiase 3 in a cytochrome c independent pathway. The 
results are from a single experiment.
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Figure 4 HSP 27 inhibits caspase 3 activation. Time course for
caspase 3 activity in DB 46 (+HSP 27) and DC 4 (-HSP 27) 
at 0, 2, 4, 6, 8 hours following induction of apoptosis by 
lOmM sodium butyrate (NaB). Error bars represent standard 
error of the means; results are reported as the average of 
three experiements. (* : p=0.05 and + = too few values to 
determine significance)
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Figure 5 HSP 27 does not directly inhibit caspase activity.
Percent of inhibition of caspase 8 and 3 by equal 
molar amounts of HSP 27. Error bars represent 
the standard error of the means. Data was averaged 
from two experiments run in triplicate. There was 
no statistically significant differences in values 
between the control and the HSP 27 containg caspase 
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Figure 6 HSP 27 does not directly inhibit caspase 9 activity. Percent 
of inhibition of caspase 9 by equal molar amounts cd* HSP 
27 or caspase 9 inhibitor. Error bars represent standard 
error of the means. Data was averaged from one exprim ait 
run in triplicate. There are no statistically significant 
differences in values between the control and the HSP 27 
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Figure 7 HSP 27 inhibits caspase 9 activation. Time course 
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Figure 8 HSP 27 can bind to cytochrome c. Western blot showing direct 
interaction between HSP 27 and cytochrome c. Lane 3 shows 
that there is a low level o f cross reactivity between the HSP 27 
antibody and cytochrome c. When both HSP 27 and cytochrome 
c are added together and immunopreciphated with an antibody 
specific for HSP 27, a strong signal for cytochrome c is observed in 
lane 8. This indicates that HSP 27 and cytochrome c form a complex in 
vitro.
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presence of various amounts of caspase 9 inhibitor. 
Error bars rqaresent standard aror of the means.
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CHAPTER 4 
DISCUSSION
Many research groups have shown that HSP 27 inhibits apoptosis but the 
mechanism for this has not been determined. Garrido et. al (12) have indirect evidence 
that HSP 27 binds to cytochrome c and thus inhibits apoptosis. In this thesis, HSP 27 
was shown to bind directly to cytochrome c. This was demonstrated, in estrogen receptor 
negative cell lines derived from MDA-MB-231 cells. The cell line DB 46 had a 
constitutrvely expressing HSP 27 vector while the DC 4 cell line had a control vector, 
which did not express HSP 27. With these cell lines, the caqiase 3, then caspase 9 and 
cytochrome c components o f the caspase cascade were evaluated.
In vivo studies revealed that HSP 27 blocks the activation of caspase 3 in the 
presence o f an apoptotic stimulus (NaB). Figure 4 (page 23) demonstrates a conq)lete 
time course. Caspase 3 activation was observed at 6 hours following exposure to NaB in 
the control transfected cell lines. These results are similar to what others have reported 
for caspase 3 activation (23). In the HSP 27 over-expressing cells, caspase 3 was not 
activated between 0 and 24 hours. This lead to the conclusion that HSP 27 might be 
directly inhibiting caspase 3 or acting at a point prior to the caspase cascade. Apoptosis 
appears not to occur at a later time because o f the cell survival data (figure 3, page 22). 
The cell survival data indicate that the cells that over-express HSP 27 are close to control 
values which indicate the HSP 27 expressing cells have not undergone apoptosis within
32
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values which indicate the HSP 27 expressing cells have not undergone apoptosis within 
fourteen days o f exposure to NaB. A direct interaction between caspase 3 and HSP 27 
was assessed. Since it had been reported that HSP 27 could inhibit serine proteases, it 
was best to investigate any inhibition o f cysteine proteases (37). When recombinant HSP 
27 and recombinant caspase 3 were added together and incubated, there was no inhibition 
in the amount o f substrate that caspase 3 could cleave (figure 5, page 24). This suggested 
that HSP 27 does not directly inhibit caspase 3.
Since HSP 27 did not inhibit caspase 3, the caspase cascade was evaluated at the 
level of caspase 9. Once again, time courses were conducted and it was determined that 
caspase 9 was activated at fifteen minutes following addition o f NaB in the control 
transfected cell line. While in the HSP 27 expressing cells, caspase 9 was not active up 
to and past 24 hours. Once again this result was consistent with published findings. Sun 
at. al. (23) reported that caspase 9 is activated at 45 minutes and peaks at about four 
hours. This thesis utilized breast cancer cells while Sun et. al. worked with Jurkat T cells. 
This may be the reason that a sharp increase and decrease was observed in breast cancer 
cells while Sun et. aL reported a steady increase in caspase 9. HSP 27 does not directly 
inhibit caspase 9 (figure 6, page 25). It was also shown that caspase 9 does play a role in 
the activation of caspase 3 (figure 10, page 29). Because there is a reduction in caspase 3 
activity if  there is a caspase 9 inhibitor present, this suggests that caspase 9 activates most 
o f the caspase 3 in the cell. The proposed caspase cascade suggests that caspase 9 is 
activated before caspase 3. The time course data support this mechanism in breast cancer 
cells since caspase 9 was activated at 15 minutes while caspase 3 was activated at 6 hours
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following exposure to NaB. Since the presence of HSP 27 is inhibiting caspase 9 
activation the caspase cascade was further evaluated at the level of cytochrome c.
The data shows that HSP 27 binds directly to cytochrome c. Garrido et. aL ( 12) 
reported that HSP 27 inhibits at the level o f cytochrome c but a direct inhibition was not 
demonstrated. Data in this thesis demonstrates that HSP 27 directly binds to cytochrome 
c (page 27, figure 8). HSP 27 may be binding to cytochrome c when it is released fi'om 
the mitochondria or after it has become part o f the apoptosome. Since HSP 27 is a 
molecular chaperone and binds to denatured proteins, it can be assumed that cytochrome 
c is denatured when it leaks out o f the mitochondria. Knowing that a direct interaction 
with cytochrome c is occurring, an attempt to overcome this inhibition was performed by 
adding more cytochrome c to cell fi'ee extracts. Using a dose response design, this 
inhibition was overcome with the addition of more cytochrome c. These results indicate 
that HSP 27 can only bind a finite amount of cytochrome c. The excess cytochrome c, 
which is not bound to HSP 27, can activate caspase 3. At the cellular level it would be 
possible that exogenous cytochrome c may be able to activate the apoptotic pathway in 
cells that over express HSP 27.
In order to initiate apoptosis via another mechanism and also to show that HSP 27 
is working at the level o f cytochrome c, granzyme B was evaluated since it is known to 
activate all known caspases. We determined the ability o f granzyme B to activate 
caspase 3 in the presence o f  HSP 27. It was shown that HSP 27 does not inhibit the 
activation o f caspase 3 by granzyme B (figure 12, page 31). These results help to 
confirm that HSP 27 does not inhibit caspase 3 activation via another pathway o f 
apoptosis. The use of granzyme B might be a way to kill breast cancer cells that over
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express HSP 27. Since granzyme B is produced in killer T cells, researchers could 
develop a T cell that can detect a cancer cell that over expresses HSP 27 and have the T 
cell distribute granzyme B to kill the cancer.
As described in the introduction, there are many known inhibitors of apoptosis.
All inhibitors o f  apoptosis bind to caspases to inhibit their activation or stop their 
activation. HSP 27 has no sequence homology to any of these other inhibitors suggesting 
that it works at another point in the caspase cascade. This thesis has demonstrated that 
HSP 27 is a novel inhibitor of apoptosis because it binds directly to cytochrome c and no 
where else in the cascade (figure 8, page 27). Also with the addition o f excess 
cytochrome c we can restart the caspase cascade which also suggests that HSP 27 only 
binds at the level o f  cytochrome c.
With the over-expression of HSP 27, cancer cells will be able to receive death 
signals (cytotoxic drugs and heat shocks) but will not undergo apoptosis. This is because 
HSP 27 is halting the caspase cascade at the level o f cytochrome c as seen in figure 13 
(page 38). When the apoptotic stress is applied, it causes a release of cytochrome c fi’om 
the mitochondria. This released cytochrome c may or may not be denatured when 
released. Since HSP 27 is known as a molecular chaperone and binds to denatured 
proteins, we can speculate that cytochrome c is denatured. We know fiom work in our 
laboratory that HSP 27 can help to maintain protein fiinction (such as citrate synthase and 
a-glucosidase) fiom thermal dénaturation. Similar studies have reported that HSP 27 
binds to citrate synthase where the enzyme retains its function (39). HSP 27 might be 
binding cytochrome c and inhibiting the formation o f the apoptosome or HSP 27 might 
be binding to cytochrome c on the apoptosome and inhibiting the activation o f caspase 9.
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HSP 27 will bind to denatured proteins independent o f its phosphorylation states (40). 
With the over-expression of HSP 27, the cell is more likely to survive an apoptotic
stimulus.
In conclusion, the hypothesis o f this study was proven to be false. It was thought 
that HSP 27 inhibited ca^ase 3 activity, but it was demonstrated that HSP 27 inhibits the 
activation o f caspase 3 and caspase 9. Therefore, our current hypothesis is that HSP 27 is 
a novel inhibitor o f apoptosis because it directly binds to cytochrome c released from the 
mitochondria. When HSP 27 binds to cytochrome c the caspase cascade is inhibited 
which leads to an inhibition of apoptosis. We have also shown that the addition o f excess 
cytochrome c will reactivate and start the caspase cascade. Granzyme B will also bypass 
the inhibitory actions o f HSP 27 and activate the caspases, hopefully, causing apoptosis 
in cancerous cells that over-express HSP 27 (figure 13, page 38).
Futine Work
Future work to complete the mechanistic outline o f HSP 27 binding to 
cytochrome c would be to determine if  cytochrome c is in the native form or a denatured 
form when released from the mitochondria. Another experiment would be to determine if 
HSP 27 can refold cytochrome c to its native forms and releases h. Both o f these 
experiments could reveal if cytochrome c is in a native or denatured form. Apoptosis 
could be induced in cells that over-express HSP 27 by adding varying concentrations of 
granzyme B. Since granzyme B does not easily cross the cell membrane, perforin would 
be used to facilitate granzyme B into the cells. When perforin is in high concentrations it 
will make holes in the cell membrane and granzyme B can enter the cell. At low
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unknown mechanism, perforin makes a hole in the vesicle and granzyme B is released 
(38). With these experiments, they will show if granzyme B can enter a cell and activate 
the caspase cascade even in the presence o f an over-expression of HSP 27. This piece of 
information might be useful in determining if  granzyme B could be used as a therapeutic 
drug for breast cancer patients.
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